1. Home
  2. PRG vs VIR Comparison

PRG vs VIR Comparison

Compare PRG & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

N/A

Current Price

$30.46

Market Cap

1.6B

ML Signal

N/A

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

N/A

Current Price

$11.72

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRG
VIR
Founded
2020
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
PRG
VIR
Price
$30.46
$11.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
10
Target Price
★ $52.00
$21.00
AVG Volume (30 Days)
663.6K
★ 1.9M
Earning Date
10-28-2026
11-04-2026
Dividend Yield
★ 1.81%
N/A
EPS Growth
N/A
★ 17.49
EPS
★ 1.80
N/A
Revenue
★ $2,409,223,000.00
$68,556,000.00
Revenue This Year
$27.00
$257.66
Revenue Next Year
$7.67
N/A
P/E Ratio
$17.17
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$25.80
$4.82
52 Week High
$47.73
$11.94

Technical Indicators

Market Signals
Indicator
PRG
VIR
Relative Strength Index (RSI) 26.82 59.75
Support Level $28.97 $8.43
Resistance Level $33.81 $11.77
Average True Range (ATR) 1.21 0.65
MACD 0.04 0.03
Stochastic Oscillator 22.41 84.43

Price Performance

Historical Comparison
PRG
VIR

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: